)
Global Newsroom
Recent News Releases
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Melbourne, Australia
- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted
CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting
Genoa, Italy
- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address the unique needs of CIDP patients.
- Presentations include new analysis from the PATH (Polyneuropathy and Treatment with Hizentra) study, the largest clinical trial in CIDP.
Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders
Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May
CSL Names Paul McKenzie as Chief Operating Officer
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]
New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients
Global Biotherapeutics Leader CSL Behring Opens Regional Headquarters at Dubai Science Park
Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Want to know more about how we are sharing stories of biotech's promise?
Read VitaCSL Behring Media Contacts
CSL Behring Production Sites
Christina Hickie
Broadmeadows, Victoria, Australia
Phone: +61 429 609 762